The management of pediatric multiple sclerosis

Journal of Child Neurology

Volumn 27, Issue 11, 2012, Pages 1384-1393

  Yeh, E Ann ^a,b   Weinstock Guttman, Bianca ^c,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c JACOBS NEUROLOGICAL INSTITUTE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

demyelination; multiple sclerosis; pediatric; therapies

Indexed keywords

AMINOTRANSFERASE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; RITUXIMAB; TERIFLUNOMIDE;

ADD ON THERAPY; ALOPECIA; ANEMIA; CARDIOTOXICITY; CHILDHOOD DISEASE; COGNITIVE DEFECT; COGNITIVE REHABILITATION; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DEPRESSION; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOTHERAPY; INFERTILITY; INJECTION SITE ABSCESS; INJECTION SITE NECROSIS; INJECTION SITE REACTION; LEUKEMIA; LEUKOPENIA; MULTIPLE SCLEROSIS; MYOCARDITIS; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SIDE EFFECT; SORE THROAT; THROMBOCYTOPENIA;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; AGE OF ONSET; CHILD; DISABLED PERSONS; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; PEDIATRICS; PLASMAPHERESIS; RECURRENCE;

EID: 84867722513     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073812452785     Document Type: Review

References (91)

1. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009 ; 15: 627-631
2. Langer-Gould A, Zhang JL, Chung J, et al. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011 ; 77: 1143-1148
3. Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology. 2002 ; 59: 1922-1928
4. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 2007 ; 6: 773-781
5. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009 ; 66: 54-59
6. Waldman AT, Gorman MP, Rensel MR, et al. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol. 2011 ; 26: 675-682
7. Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler. 2004 ; 10: 89-91
8. Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004 ; 63: 2028-2033
9. Elovaara I, Kuusisto H, Wu X, Rinta S, Dastidar P, Reipert B. Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol. 2011 ; 34: 84-89
10. Straussberg R, Schonfeld T, Weitz R, et al. Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins. Pediatr Neurol. 2001 ; 24: 139-143
11. Spalice A, Properzi E, Lo Faro V, et al. Intravenous immunoglobulin and interferon: successful treatment of optic neuritis in pediatric multiple sclerosis. J Child Neurol. 2004 ; 19: 623-626
12. Shahar E, Andraus J, Savitzki D, et al. Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins. J Child Neurol. 2002 ; 17: 810-814
13. Schilling S, Linker RA, Konig FB, et al. Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients. Nervenarzt. 2006 ; 77: 430-438
14. Takahashi I, Sawaishi Y, Takeda O, et al. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol. 1997 ; 17: 83-87
15. Mogami Y, Yamada K, Toribe Y, et al. Successful treatment with additional plasmapheresis for the exacerbation of acute neurological symptoms in a girl with multiple sclerosis. No To Hattatsu. 2011 ; 43: 36-40
16. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology. 1993 ; 43: 1100-1104
17. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011 ; 76: 294-300
18. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology. 1993 ; 43: 655-661
19. Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996 ; 39: 285-294
20. Randomized double-blind placebo-controlled study of interferon ?-1a in relapsing/remitting multiple sclerosis. Lancet. 1998 ; 352: 1498-1504
21. Mikaeloff Y, Caridade G, Tardieu M, Suissa S. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol. 2008 ; 12: 205-209
22. Mikaeloff Y, Moreau T, Debouverie M, et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr. 2001 ; 139: 443-446
23. Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005 ; 64: 888-890
24. Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006 ; 67: 511-513
25. Waubant E, Hietpas J, Stewart T, et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics. 2001 ; 32: 211-213
26. Ghezzi A, Amato MP, Capobianco M, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler. 2005 ; 11: 420-424
27. Ghezzi A, Amato MP, Annovazzi P, et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci. 2009 ; 30: 193-199
28. Ghezzi A, Amato MP, Capobianco M, et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci. 2007 ; 28: 127-132
29. Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006 ; 66: 472-476
30. Yeh EA, Waubant E, Krupp LB, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol. 2011 ; 68: 437-444
31. Ghezzi A, Banwell B, Boyko A, et al. The management of multiple sclerosis in children: a European view. Mult Scler. 2010 ; 16: 1258-1267
32. Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012 ; 18: 116-127
33. Dhib-Jalbut S. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci. 2002 ; 201: 71-77
34. Johnson K, Brooks B, Cohen J, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995 ; 45: 1268-1276
35. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009 ; 72: 1976-1983
36. Ghezzi A. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian co-operative study. Neurol Sci. 2005 ; 26 (Suppl 4). S183 - S186
37. Kornek B, Bernert G, Balassy C, et al. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003 ; 34: 120-126
38. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
39. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
40. Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011 ; 77: 1061-1067
41. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003 ; 71: 115-123
42. Polo C, Perez JL, Mielnichuck A, et al. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect. 2004 ; 10: 640-644
43. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010 ; 68: 295-303
44. VanAssche G, Ranst MV, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005 ; 353: 362-368
45. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005 ; 353: 369-374
46. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005 ; 353: 375-381
47. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 ; 354: 924-933
48. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012 ; 18: 143-152
49. Borriello G, Prosperini L, Luchetti A, Pozzilli C. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol. 2009 ; 13: 67-71
50. Huppke P, Stark W, Zurcher C, et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol. 2008 ; 65: 1655-1658
51. Ghezzi A, Pozzilli C, Grimaldi LM, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology. 2010 ; 75: 912-917
52. Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord. 2010 ; 3: 293-299
53. Hartung H, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet. 2002 ; 360: 2018-2025
54. Zipoli V, Portaccio E, Hakiki B, et al. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci. 2008 ; 266: 25-30
55. Ellis R, Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it?. Mult Scler. 2009 ; 15: 505-508
56. Pascual AM, Tellez N, Bosca I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler. 2009 ; 15: 1303-1310
57. Kornek B, Bernert G, Rostasy K, et al. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis. Neuropediatrics. 2011 ; 42: 7-12
58. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008 ; 63: 395-400
59. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688
60. Brown BA, Torabi M. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Saf. 2011 ; 34: 117-123
61. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology. 2010 ; 74: 1860-1867
62. Karenfort M, Kieseier BC, Tibussek D, et al. Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol. 2009 ; 51: 159-161
63. Patti F, Amato MP, Filippi M, et al. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J Neurol Sci. 2004 ; 223: 69-71
64. Portaccio E, Zipoli V, Siracusa G, et al. Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Mult Scler. 2003 ; 9: 446-450
65. Weiner H, Ackin G, Orav E, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 ; 43: 910-918
66. Makhani N, Gorman MP, Branson HM, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009 ; 72: 2076-2082
67. Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology. 2007 ; 69: 785-789
68. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 ; 9: 381-390
69. Gorman MP, Tillema JM, Ciliax AM, et al. Daclizumab use in patients with pediatric multiple sclerosis. Arch Neurol. 2012 ; 69: 78-81
70. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 387-401
71. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009 ; 72: 73-79
72. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 ; 365: 1293-1303
73. Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010 ; 75: 1134-1140
74. Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008 ; 70: 1891-1897
75. Banwell BL, Anderson PE. The cognitive burden of multiple sclerosis in children. Neurology. 2005 ; 64: 891-894
76. MacAllister WS, Belman AL, Milazzo M, et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology. 2005 ; 64: 1422-1425
77. Smerbeck A, Parrish J, Serafin D, et al. Visual-cognitive processing deficits in pediatric multiple sclerosis. Mult Scler. 2011 ; 17: 449-456
78. Sastre-Garriga J, Alonso J, Renom M, et al. A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis. Mult Scler. 2011 ; 17: 457-467
79. Yeh EA, Weinstock-Guttman B, Smerbeck A, Benedict R, Parrish J. the Netherlands: Amsterdam ; 2011 :
80. MacAllister WS, Christodoulou C, Troxell R, et al. Fatigue and quality of life in pediatric multiple sclerosis. Mult Scler. 2009 ; 15: 1502-1508
81. MacAllister WS, Boyd JR, Holland NJ, et al. The psychosocial consequences of pediatric multiple sclerosis. Neurology. 2007 ; 68: S66 - S69
82. Mowry E, Julian L, Chabas D, et al. Health-related qulaity of life is reduced in children with early multiple sclerosis. Mult Scler. 2008 ; 14: S147
83. Gualano B, Sa Pinto AL, Perondi B, et al. Evidence for prescribing exercise as treatment in pediatric rheumatic diseases. Autoimmun Rev. 2010 ; 9: 569-573
84. Houghton KM, Tucker LB, Potts JE, McKenzie DC. Fitness, fatigue, disease activity, and quality of life in pediatric lupus. Arthritis Rheum. 2008 ; 59: 537-545
85. White PD, Goldsmith KA, Johnson AL, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 2011 ; 377: 823-836
86. Gordon BA, Knapman LM, Lubitz L. Graduated exercise training and progressive resistance training in adolescents with chronic fatigue syndrome: a randomized controlled pilot study. Clin Rehabil. 2010 ; 24: 1072-1079
87. Nunez M, Fernandez-Sola J, Nunez E, et al. Health-related quality of life in patients with chronic fatigue syndrome: group cognitive behavioural therapy and graded exercise versus usual treatment. A randomised controlled trial with 1 year of follow-up. Clin Rheumatol. 2011 ; 30: 381-389
88. McCullagh R, Fitzgerald AP, Murphy RP, Cooke G. Long-term benefits of exercising on quality of life and fatigue in multiple sclerosis patients with mild disability: a pilot study. Clin Rehabil. 2008 ; 22: 206-214
89. Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol. 1996 ; 39: 432-441
90. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler. 2002 ; 8: 161-168
91. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology. 2004 ; 62: 2058-2064